Purpose: To explore a method for the early, rapid and accurate diagnosis of Wolfram syndrome 1 (WS1) and further enrich the spectrum of WFS1 mutations in the Chinese population.
INTRODUCTION
Wolfram syndrome 1 (WS1, MIM# 222300) is a rare inherited disease, characterized by diabetes insipidus), diabetes mellitus (DM), optic atrophy (OA), and deafness, and is therefore also known as DIDMOAD. It was first described in 1938 (Wolfram and Wagener, 1938) . Other findings include cataracts, pigmentary retinopathy, hydronephrosis, hydroureter, neurogenic bladder, ataxia, and psychiatric disorders. Patients may also present with cardiomyopathy, hypothyroidism, and hypogonadism. The estimated prevalence ranges from 1:68,000 to 1:770,000 (Fraser and Gunn 1977; Barrett et al., 1995; Medlej et al., 2004; Matsunaga et al., 2014) . The age at death varies from 25 to 49 years (median age is 30 years) and is usually due to brain stem atrophy resulting in respiratory failure (Barrett et al., 1995) . There is currently no effective treatment. The clinical diagnostic criteria for WS1 are juvenile-onset DM and OA. It can be easily misdiagnosed as type 1 DM before other symptoms, such as OA, present. It is crucial to combine genetic diagnosis with clinical manifestations to obtain an early diagnosis and confirmation of WS1.
WS1 is an autosomal recessive condition, caused by mutations in the WFS1 gene [Online Mendelian Inheritance in Man (OMIM) 606201]. The WFS1 gene is mapped to human chromosome 4p16.1 (Strom et al., 1998) and is composed of eight exons, spanning 33.4 kb of genomic DNA. Exon 8 is the largest exon, and exons 2-7 are small coding exons, and exon 1 is noncoding (Inoue et al., 1998) . WFS1 encodes wolframin, a transmembrane protein that localizes primarily in endoplasmic reticulum (ER) membranes and is ubiquitously expressed at the highest levels in the brain, pancreas, heart, and insulinoma betacell lines (Hofmann et al., 2003) . Wolframin is a transmembrane glycoprotein consisting of 890 amino acids with a molecular mass of 100.29 kD (Takeda et al., 2001) . It is composed of nine transmembrane segments and is embedded in the membrane with an N(cyt)/C(lum) topology (Hofmann et al., 2003) . Its function has not yet been fully clarified. Some studies (Fonseca et al., 2010; Hara et al., 2014) have shown that WFS1 appears to be important to the negative regulation of ER stress. Osman et al. (2003) proposed that wolframin may play an important role in the regulation of intracellular Ca 2+ homeostasis. In addition, Zatyka et al. (2008) noted that an interaction with WFS1 is essential for Na + /K + ATPase beta-1 subunit maturation in the ER and that the loss of this interaction may contribute to the pathogenesis of WS1.
The Human Gene Mutation Database (HGMD) has so far recorded 393 variants in WFS1. Except for WS1, it is also thought to underlie some autosomal dominant conditions that are less severe. Given the clinical and genetic heterogeneity of WS1, combining genetic diagnosis with clinical features is an effective supplementary diagnostic method. In addition, genetic diagnosis is essential for prognosis evaluation, individualized treatment, genetic counseling and carrier screening. At present, limited data are available on which WFS1 mutations are associated with WS1 in the Chinese population, and only a small number of case reports have been published. No prevalence has been reported in China. In this study, we used NGS to evaluate five Chinese patients affected by WS1, thus increasing the spectrum of WFS1 mutations by adding four novel variants. We have also reviewed their clinical features.
MaTeRIalS aND MeThODS

Subjects and ethics Statement
We collected 279 patients with unexplained OA who presented at the Eye and ENT Hospital of Fudan University from 2016 to 2018. Patients with infection, ischemia, optic neuritis, myelitis, and tumors were excluded. The study was performed according to the Declaration of Helsinki and approved by the Ethics Committee of the Eye and ENT Hospital of Fudan University. Written informed consent was obtained from all the subjects or their guardians to participate in this study and for the publication of these data.
Clinical evaluations
All patients underwent detailed clinical evaluations, including medical history, family history, and basic and auxiliary examinations. The chief complaint, the course of the disease and accompanying symptoms were recorded in detail. In addition, every patient was asked whether his parents were consanguineous and whether other family members were affected. Basic and auxiliary examinations included best corrected visual acuity, tonometry, color vision (Ishihara color plate), slit-lamp examination, dilated fundus examination, frequency domain optical coherence tomography (Cirrus OCT 5000, Carl Zeiss Meditec, Inc., Dublin, CA, United States), Humphrey VisualField Analyzer (Carl Zeiss Meditec, Inc., Dublin, CA, United States), full-field electroretinography (ERG), and visual evoked potential (VEP) (LKC UTAS E3000 LKC Technologies, Inc., United States) tests. A preliminary assessment of systemic conditions was performed by measuring the fasting blood glucose concentration, puretone audiometry, and urine specific gravity. Orbital magnetic resonance imaging or computed tomography was used to exclude neoplasms.
Genetic analyses
We designed a high-throughput microarray in collaboration with BGI-Shenzhen (Shenzhen, Guangdong, China). It contained the exon sequences of 792 genes ( Supplementary  Table S1 ) as well as 30 bp on either side of the exonic region, selected on the basis of OMIM database, the ophthalmic disease gene database, and related literature. Only genes known to be involved in human inherited eye diseases, including syndromes with ocular manifestation, were selected. Genes found only in animal models of eye diseases were not included. Genomic DNA was extracted from peripheral blood obtained from the probands and their family members using FlexiGene DNA Kits (Qiagen, Venlo, the Netherlands) according to standard procedures, sheared into 150-250 bp fragments, and captured with the Agilent SureSelect Target Enrichment Kit (Agilent Technologies, Inc., USA). Enriched libraries were sequenced on the Illumina HiSeq 2000 platform (Illumina, Inc., San Diego, CA, United States), and reads were aligned to the reference human genome (UCSC hg38) using the Burrows-Wheeler aligner version 0.7.10 (BWA-MEM). The following databases were used for the annotation: 1,000 Genomes Project, 1,000 Genomes in the East Asian population, Single Nucleotide Polymorphism Database, the Exome Aggregation Consortium, and Genome Aggregation Database. Then, we retained variants with a minor allele frequency (MAF) < 0.1% to filter out possible non-deleterious variants based on MAF of each variant in these five databases. In addition, we performed the variant prioritizations based on MAF, potential deleterious effect and mutation reports in public databases such as HGMD, OMIM, and ClinVar. Furthermore, we analyzed the evolutionary conservation of the mutations online. Finally, Sanger sequencing and cosegregation analyses were performed within families. If no suspected pathogenic variant was found, Sanger sequencing was performed to check for the presence of the three primary mitochondrial DNA mutations (m.3460G > A, m.11778G > A, m.14484T > C) (Yen et al., 2006) . The cDNA NM_006005.3 and protein NP_005996.2 sequences were used for the mutation nomenclature. Variants were classified according to the American College of Medical Genetics.
ReSUlTS
Of the 279 patients with unexplained OA, five from four unrelated families carried compound heterozygous mutations in WFS1, and all the variants cosegregated with the phenotypes observed in these families. The main clinical and genetic characteristics of the five patients are listed in Table 1 and Table  2 , and the pedigrees of the four families (A-D) are presented in Figure 1A . Family history was clearly reported in three patients, whereas two patients were sporadic. Seven variants of WFS1 were identified; these included four novel variants (p.W540G, p.K634*, p.F770C, and p.Q584P) and three known variants (P.G674R, P.Tyr508Cysfs*34, and P.G702D) (Khanim et al., 2001; Aluclu et al., 2006; Gasparin et al., 2009 (Sun 1986; Nan and Cou, 1987; Wu 1996; Long et al., 1997; Shi et al., 1998; Feng and Chen, 2002; Chai et al., 2003; Li et al., 2003; Wang and Wang, 2004; Fang et al., 2005; Li et al., 2005; Shi et al., 2005; Lv et al., 2006; Lu et al., 2008; Zhu et al., 2008; Hong et al., 2009; Zhang et al., 2009; Xu and Li, 2011; Fan et al., 2013; Wang and Li, 2011; Xu et al., 2013; Peng et al., 2015; Wang et al., 2014; Du et al., 2017; Ni et al., 2017; Duan et al., 2018) . However, only 10 patients were confirmed by genetic testing (Table 3) , and only nine variants of WFS1 have been reported in the Chinese population. Our study reports five Chinese patients and further enriches the spectrum of WFS1 mutations. In addition, It is worth noting that c.2020G > A(P.G674R) was recurrent in this study and was identified in two unrelated families. The allele frequency of this variant in East Asian populations is 0.000231965 according to the gnomAD database. Multiple orthologous sequence alignment (MSA) around codon 674 demonstrated this and neighboring residues are highly conserved amino acids in WFS1 (Figure 2) . Furthermore, four prediction tools, including mutationtaster software, SIFT, LRT, and FATHMM, predicted that this variant is deleterious. Therefore, it suggested that p.G674R is likely to be a pathogenic variant with higher prevalence in the Chinese population.
Family a
A 27-year-old female patient came for genetic testing. She was found to have DM when she was 12 years old and was diagnosed with bilateral OA 5 years later. In addition, her medical history revealed nephritis. She had an affected younger brother with similar symptoms. He presented with OA when he was 7 years old and was diagnosed with DM at the age of 11. Pure-tone audiometry revealed sensorineural hearing loss, while his urinespecific gravity was normal. Their vision was 20/400 OU. Genetic analysis identified a reported variant c.2020G > A (p.G674R, inherited paternally) (Khanim et al., 2001 ) and a novel variant c.1618T > G (p.W540G, inherited maternally) of WFS1 in both the proband and her brother (Figure 1B) . Parental examination and testing were normal. All patients carried two compound heterozygous mutations in the WFS1 gene.
Family B
A 12-year-old girl was found to have bilateral OA when she was 8 years old. She was the only affected family member. Past medical history showed a normal delivery, normal growth and development. Best corrected visual acuity was 20/30 with -4.50 sph OD and -0.25 sph OS, and color vision was abnormal. Frequency domain optical coherence tomography showed that the retinal nerve fiber layer (RNFL) and macular ganglion cell complex were thinning in four quadrants. The visual field revealed local decreased visual sensitivity in the right eye and a central scotoma in the left eye. Fundus examination showed that the temporal optic nerve was pale in the right eye and that all quadrants were pale in the left eye, while full-field ERG and VEP were normal. Orbital magnetic resonance imaging confirmed bilateral OA. In addition, puretone audiometry, urine specific gravity and fasting blood glucose concentration were normal. Genetic analysis showed a previously reported pathogenic variant associated with WS1 in her WFS1 gene (c.2020G > A, p.G674R) (Khanim et al., 2001) , which was inherited from her clinically normal mother. In addition, there was a novel variant c.1900A > T (p.K634*) identified in the girl, which was inherited from her clinically normal father.
Family C
A 37-year-old male patient came for evaluation of OA, with which he was diagnosed when he was 11 years old. Examination Het, heterozygous; Hom, homozygous; WS1, Wolfram syndrome type 1. The other two patients were identified as having three WFS1 mutations in exon 8, but detailed results were unavailable (Duan et al., 2018) . revealed visual acuity of 20/400 in each eye. Fundus examination showed pale optic discs in both eyes. Pattern VEP showed that the time to the P1 wave peak was delayed and its amplitude diminished. In addition, visual fields were constricted in both eyes. The peripapillary RNFL was thinning in the superior and inferior quadrants while macular ganglion cell complex was thinning in all four quadrants. Orbital computed tomography confirmed bilateral OA. He had no systemic findings. Puretone audiometry, urine specific gravity and fasting blood glucose concentration were normal. Genetic analysis found a reported variant c.1522_1523delTA (p.Tyr508Cysfs*34, inherited paternally) (Aluclu et al., 2006 ) and a novel variant c.2309T > G (p.F770C, inherited maternally) of WFS1 in the proband. His mother was diagnosed with DM 10 years prior. Parental ophthalmic examination and testing were normal.
Family D
A 28-year-old male patient presented for genetic counseling. He presented with bilateral OA when he was 8 years old and was diagnosed with DM 20 years prior along with the clinical manifestations of polydipsia and polyuria. He presented with polyphagia and transient hand tremor for 3 months. In addition, he had enuresis, urgent and frequent urination, impotence, premature ejaculation and epididymitis. He had been constipated in recent months. Examination revealed visual acuity of 20/200 and 20/300 in the right and left eyes, respectively. The peripapillary RNFL showed thinning in the superior, temporal and inferior quadrants of the left eye, while thinning was found in all four quadrants of the right eye. VEP and ERG were abnormal, and he had visual field defects. Family history revealed that he had an affected sister who had poor vision since childhood and died of nephritis at the age of 25. Parental examination and testing were normal. Genetic analysis showed that he carried compound heterozygous mutations of WFS1: a reported variant c.2105G > A (p.G702D, inherited maternally) (Gasparin et al., 2009 ) and a novel variant c.1751A > C (p.Q584P, inherited paternally). His clinically normal son and daughter both carried a heterozygous variant c.1751A > C (p.Q584P) of WFS1.
DISCUSSION
In this study, by using genetic testing based on NGS we were able to diagnose five WS1 patients out of 279 patients with previously unexplained OA. The clinical diagnostic criteria for WS1 are juvenile-onset DM and OA. It is very difficult to diagnose WS1 at an early stage, and this is especially true for atypical WS1. NGS is a high-throughput approach for efficiently sequencing large gene pools at lower costs and can be used to identify rare disease genes. In families B and C, while the two probands presented with only OA, genetic analysis based on NGS made it possible to diagnose and confirm WS1 early. WS1 is a progressive neurodegenerative disease mainly affecting pancreatic beta cells and neuronal cells (Gerbitz, 1999; Yamada et al., 2006) . Therefore, early diagnosis is crucial for patients and their families. This is beneficial to the systematic evaluation, monitoring and management of complications to improve the quality of life and delay the progression of the disease. Finally, it provides a genetic basis for carrier testing, and if desired, for preimplantation diagnostic testing.
Although the HGMD has recorded 263 WFS1 mutations associated with WS1 thus far, 62.5% (5/8) of the mutations identified in our study were novel. Among the 263 identified mutations, there were 109 missense mutations, 50 nonsense mutations, 60 small deletion mutations, and 25 small insertion mutations. These mutations were mainly concentrated in exon 8. Khanim F et al.(Khanim et al., 2001) identified the mutations in WFS1 FIGURe 2 | Protein sequence alignment of human WFS1 and its orthologs. Codon 674 and its subsequent sequences were highly conserved amino acids in WFS1 across different species.
in 90% of WS1 patients and found they were mainly compound heterozygous mutations, in accordance with our study. In family A, the proband and her brother had the same mutations in WFS1, but their phenotypes were not exactly the same. D' Annunzio et al. (2008) evaluated six WS1 patients in five Italian families and noted that the same mutation could lead to different phenotypes, also consistent with our study. This finding suggested that the pathogenesis of WS1 was not only dependent on the mutation of WFS1, but also may be related to other genetic or environmental factors, such as modifier genes.
de Heredia et al. (2013) analyzed genetic data in 412 WS1 patients reported since 1998, and found no major mutation hot spots; only the following six mutations were found in more than 5% of patients: c.2649delC (p.Phe884Serfs*68, 7.42%), c.1230_1233del (p.Val412Serfs*29, 6.82%), c.409_424dup (p.Val142Glyfs*110, 6.53%), c.2119G > A (p.V707I, 6.23%), c.1362_1377del (p.Tyr454*, 5.64%), and c.1243_1245del (p.Val415del, 5.34%). In our study, c.2020G > A (p.G674R) was the most prevalent alteration in our Chinese patients and was highly conserved in different species during evolution. This suggests that the mutation may impair the key functions of the protein. Several studies have reported that the variant c.2020G > A (p.G674R) combined with c.2020G > A (p.G674R) and c.1620delGTG (Trp540del) respectively resulted in the occurrence of WS1 (Khanim et al., 2001; Aloi et al., 2012) . However, more samples are required to determine whether this is a common pathogenic variant in the Chinese population.
At present, only 47 Chinese WS1 patients have been reported since 1986. Furthermore, only 10 of these patients were confirmed by genetic testing. Given the specificity of ethnicity and the complexity of genotype-phenotype relationship, large cohort studies in the future are essential to elucidate the genotypephenotype relationship of WS1 in the Chinese population. Our study further enriches the spectrum of WFS1 mutations, which is currently based on limited data, making our findings of great significance, especially in the Chinese population.
CONClUSION
NGS has become a powerful method for the detection of ophthalmic disorders with high clinical and genetic heterogeneity. Implementing comprehensive measures to slow the progression of diseases is essential not only in early diagnosis but also in risk evaluation, individualized treatment and carrier screening for probands and their families. Precise diagnosis based on clinical manifestation and genetic testing will become the gold standard for the diagnosis of hereditary eye diseases and syndromes in the future.
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